Press releases

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Nov. 1, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Michael Benkowitz, President and Chief Operating Officer of United...

Amendment expands program from a singular focus on the bioprinting of human lung scaffolds to the development and demonstration of two additional human organs Amendment will become effective...

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Oct. 27, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2021 financial results before the...

Tyvaso DPI™ BREEZE pharmacokinetic data demonstrate similar exposure and lower variability for Tyvaso DPI compared with Tyvaso®Ten abstracts covering Tyvaso (treprostinil) Inhalation Solution, Orenitram® (treprostinil)...

Draft label contains both PAH and PH-ILD indications; no contraindications and no boxed warning Complete response cites an open inspection issue at a third-party analytical testing facility; no other deficiencies...

A total of 10 abstracts reinforce United Therapeutics' commitment to advancing research in pulmonary hypertension Additional subgroup analyses evaluate data from the Tyvaso® INCREASE study in PH-ILD Additional new...

Conversion officially aligns corporate charter with longstanding commitment to improve the lives of patients while creating sustainable shareholder value in a responsible manner SILVER SPRING, Md. and RESEARCH TRIANGLE...

In subjects with PAH, transition from Tyvaso® to Tyvaso DPI™ demonstrated safety and tolerance with significant improvements in six-minute walk distance, device preference and satisfaction, and patient reported...

- Neuroblastoma is the most common cancer in infants less than one year old and the third-most common pediatric cancer in children less than 15 years old, accounting for 15 percent of childhood cancer deaths...

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Aug. 24, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced it will present data from a clinical trial studying Tyvaso...

Tyvaso® (treprostinil) Inhalation Solution net revenue growth of 29% year over year; total net revenue growth of 23% year over yearTyvaso DPI™ NDA under review with FDA action expected in October 2021 SILVER SPRING, Md...

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Aug. 3, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of...